孕激素受体膜组分1在乳腺癌发生机制中作用的研究进展

doi:10.3969/j.issn.1006-7795.2015.04.013

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (4): 583-587.doi: 10.3969/j.issn.1006-7795.2015.04.013

• 更年期与妇科生殖内分泌 • 上一篇下一篇

孕激素受体膜组分1在乳腺癌发生机制中作用的研究进展

张颖¹, 阮祥燕^1,2, Alfred O. Mueck^1,2

1. 首都医科大学附属北京妇产医院内分泌科, 北京 100026;
2. 德国图宾根大学妇产医院内分泌与绝经中心, 德国, 图宾根 D-72076

收稿日期:2015-05-22 出版日期:2015-08-21 发布日期:2015-07-17
通讯作者: 阮祥燕 E-mail:ruanxiangyan@163.com
基金资助:
国家自然科学基金(81172518),北京市科技新星交叉合作项目(Z14111000180000),北京市卫生系统高层次卫生技术人才培养计划项目(2014-2-016),首都医科大学附属北京妇产医院学科带头人项目(2013-1)。

Progress in research on possible role of progesterone receptor membrane component 1(PGRMC1) in the mechanism of breast cancer development

Zhang Ying¹, Ruan Xiangyan^1,2, Alfred O. Mueck^1,2

1. Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China;
2. Department of Endocrinology and Menopause, University Women's Hospital of Tuebingen, Tuebingen D-72076, Germany

Received:2015-05-22 Online:2015-08-21 Published:2015-07-17
Supported by:
This study was supported by National Natural Science Foundation(81172518); Beijing Nova Program(Z14111000180000); Beijing Municipality Health Technology High-level Talent(2014-2-016); Project of Discipline Leader, Beijing Obstetrics and Gynecology Hospital, Capital Medical University(2013-1).

摘要/Abstract

摘要：

乳腺癌是导致女性死亡的主要癌症之一,但目前为止关于乳腺癌的发生机制尚未完全明确。唯一一项全球大型安慰剂对照研究,妇女健康启动项目(Women's Health Initiative,WHI)指出,雌孕激素联合治疗组乳腺癌风险增高,单一雌激素治疗组妇女的乳腺癌风险没有增加,反而有降低,说明在激素补充治疗(hormone replacement therapy,HRT)治疗中孕激素对乳腺癌风险具有负面影响。针对此结论开展了很多体外研究,发现雌孕激素联合治疗可以明显促进孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)表达阳性的乳腺癌细胞的增生。针对此结论,北美绝经学会官方科学杂志Menopause对此给予特别的编者按:"WHI研究中雌孕激素联合治疗组妇女乳腺癌风险增加是否可以用PGRMC1的作用来解释?PGRMC1是否可以作为一个乳腺癌风险潜在的标志物？PGRMC1高表达者是否可确定为乳腺癌易感者？"本文将就此方面的研究进行综述。

关键词: 孕激素受体膜组分1, 乳腺癌, 雌激素受体, 孕激素受体

Abstract:

Breast cancer is one of the most common leading cause of cancers death in women world-wide. But the mechanism of breast cancer development is still unclear. The only placebo-controlled study, the Women's Health Initiative(WHI) demonstrated that breast cancer risk mainly is dependent on the progestogen component since only in the combined estrogen/progestogen arm, but not in the estrogen-only arm this risk was seen to increase the risk. According to this finding, our previous investigation point towards an important role of progesterone receptor membrane component 1(PGRMC1) in hormone related breast cancer risk. This finding got great attention from the related field in the world. An editorial published in the journal Menopause raised the following questions: "Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Can the PGRMC1 become to be a potential marker in the future? Will the women with high expression of PGRMC1 be breast cancer susceptible people?" We will review the results of related researches.

Key words: progesterone receptor membrane component 1, breast cancer, estrogen receptor, progestogen receptor

中图分类号:

R711

张颖, 阮祥燕, Alfred O. Mueck. 孕激素受体膜组分1在乳腺癌发生机制中作用的研究进展[J]. 首都医科大学学报, 2015, 36(4): 583-587.

Zhang Ying, Ruan Xiangyan, Alfred O. Mueck. Progress in research on possible role of progesterone receptor membrane component 1(PGRMC1) in the mechanism of breast cancer development[J]. Journal of Capital Medical University, 2015, 36(4): 583-587.

参考文献

[1] Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010[J]. Chin J Cancer Res, 2014,26(1):48-58.
[2] Rossouw J E, Anderson G L, Prentice R L, et al. Risks and bene-fits of estrogen plus progestin in healthy postmenopausal women[J]. JAMA, 2002,288(3):321-333.
[3] Fraser I S. Reanalysis of data from the Million Women Study[J]. J Fam Plann Reprod Health Care, 2012,38(2):136.
[4] Lagiou P, Georgila C, Samoli E, et al. Estrogen and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk[J]. Int J Cancer, 2009,124(2):440-442.
[5] Schoonen W G, Joosten J W, Kloosterboer H J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines[J]. Steroid Biochem Mol Biol, 1995,55(3-4):423-437.
[6] Cappelletti V, Miodini P, Fioravanti L, et al. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines[J]. Anticancer Res, 1995,15(6B):2551-2555.
[7] Krmer E A, Seeger H, Krmer B, et al. The effect of progesterone, testosterone and synthetic progestins on growth factor- and estradiol-treated human cancerous and benign breast cells[J]. Eur J Obstet Gynecol Reprod Biol, 2006,129(1):77-83.
[8] Althuis M D, Fergenbaum J H, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature[J]. Cancer Epidemiol Biomarkers Prev, 2004,13(10):1558-1568.
[9] Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development[J]. Climacteric, 2013,16(5):509-513.
[10] 张颖,阮祥燕,田玄玄,等.孕激素受体膜组分1(PGRMC1)在乳腺癌发生风险方面的研究进展[J].首都医科大学学报,2013,34(4):496-500.
[11] Meyer C, Schmid R, Scriba P C, et al. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes[J]. Eur J Biochem, 1996,239(3):726-731.
[12] Cahill M A. Progesterone receptor membrane component 1: an integrative review[J]. J Steroid Biochem Mol Biol, 2007,105(1-5):16-36.
[13] Hughes A L, Powell D W, Bard M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes[J]. Cell Metab, 2007,5(2):143-149.
[14] Crudden G, Chitti R E, Craven R J. Hpr6(heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs[J]. J Pharmacol Exp Ther, 2006,316(1):448-455.
[15] 纪术峰,吴爱国,杨华峰.孕激素膜受体1在乳腺癌的表达及生物学意义[J].南方医科大学学报,2012,32(5):635-638.
[16] Crudden G, Loesel R, Craven R J. Overexpression of the cytochrome p450 activator hpr6(heme-1 domain protein/human progesterone receptor) in tumors[J]. Tumour Biol, 2005,26(3):142-146.
[17] Ji S, Wu A, Yang H. Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2012,32(5):635-638.
[18] Neubauer H, Clare S E, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1[J]. Breast Cancer Res, 2008,10(5):R85.
[19] Causey M W, Huston L J, Harold D M, et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging[J]. J Surg Res, 2011,171(2):615-622.
[20] Peluso J J, Pappalardo A, Losel R, et al. Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability[J]. Biol Reprod, 2005,73(2):261-270.
[21] Crudden G, Loesel R, Craven R J. Overexpression of the cytochrome p450 activator hpr6(heme-1 domain protein/human progesterone receptor) in tumors[J]. Tumour Biol, 2005,26(3):142-146.
[22] Neubauer H, Yang Y, Seeger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J]. Menopause, 2011,18(8):845-850.
[23] Schneck H, Ruan X, Seeger H, et al. Membrane-receptor initiated proliferative effects of dienogest in human breast cancer cells[J]. Gynecol Endocrinol, 2013,29(2):160-163.
[24] Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric, 2012,15(5):467-472.
[25] Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1: possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013,20(5):504-510.
[26] Ruan X, Schneck H, Schultz S, et al. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells[J]. Gynecol Endocrinol, 2012,28(11):863-866.
[27] Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy[J]. Obstet Gynecol, 2009,113(1):65-73.
[28] Krebs C J, Jarvis E D, Chan J, et al. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors[J]. Proc Natl Acad Sci USA, 2000,97(23):12816-12821.
[29] Neubauer H, Chen R, Schneck H, et al. Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells[J]. Horm Mol Biol Clin Investig, 2011,6(1):185-192.
[30] Neubauer H, Clare S E, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1[J]. Breast Cancer Res, 2008,10(5):R85.
[31] 桑晶,孙勇,韩玉贞.乳腺癌干细胞激素受体与HER-2表达生物学意义的分析[J].中华肿瘤防治杂志,2013,20(12):926-929.
[32] 曹丹霞,何建蓉,沈坤炜,等.激素受体和HER-2及Ki-67预测乳腺癌新辅助化疗疗效价值的分析[J].中华肿瘤防治杂志,2012,19(13):1000-1003.
[33] 刘建中,张凯松,徐佳,等.乳腺癌组织中CerbB-2、ER与PR表达以及对预后的影响[J].临床误诊误治,2012,25(1):62-64.
[34] Seeger H, Wallwiener D, Mueck A O. Effects of estradiol and progestogens on TNF-alpha induced changes of biochemical markers for breast cancer growth and metastasis[J]. Gynecol Endocrinol, 2008,24(10):576-579.
[35] Hand R A, Craven R J. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells[J]. J Cell Biochem, 2003,90(3):534-547.
[36] Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk[J]. Horm Mol Biol Clin Investig, 2011,6(1):185-192.
[37] Swiatek-De Lange M, Stampfl A, Hauck S M, et al. Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells[J]. Glia, 2007,55(10):1061-1073.
[38] Liu L, Wang J, Zhao L, et al. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2[J]. Endocrinology, 2009,150(7):3186-3196.

孕激素受体膜组分1在乳腺癌发生机制中作用的研究进展

Progress in research on possible role of progesterone receptor membrane component 1(PGRMC1) in the mechanism of breast cancer development

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵越, 阮祥燕, 程姣姣, 谷牧青, 许新, 王月姣. 乳腺癌中PGRMC1表达与临床病理参数的相关性[J]. 首都医科大学学报, 2022, 43(3): 350-356.
[2]	魏常胜, 骆成玉, 张树琦. 环乳晕切口联合乳腔镜腋窝淋巴结清扫在早期乳腺癌保乳手术中的应用[J]. 首都医科大学学报, 2021, 42(6): 1014-1020.
[3]	中华预防医学会妇女保健分会; 中国人体健康科技促进会妇科内分泌与生育力促进专委会. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识(2021版)[J]. 首都医科大学学报, 2021, 42(4): 672-677.
[4]	阮祥燕, 杨瑜, 卢丹, 杜娟, 程姣姣, 谷牧青, 李扬璐, 金凤羽, 段微, 代荫梅, 鞠蕊, 许新, MatthiasKorell, AlfredO.Mueck. 中国首例乳腺癌患者冻存卵巢组织移植成功报道及文献复习[J]. 首都医科大学学报, 2021, 42(2): 177-182.
[5]	杨阳, 康骅, 赵菁, 凌煜玮, 赵烨, 王亚军, 戎冬冬. 术前乳腺MRI对乳腺癌保乳手术切缘评估的回顾性分析[J]. 首都医科大学学报, 2020, 41(6): 943-953.
[6]	王爱婷, 鄢丹, 齐宪荣. 包载多西他赛的聚合物胶束抑制小鼠乳腺癌转移作用研究[J]. 首都医科大学学报, 2020, 41(2): 225-230.
[7]	王维, 张紫寒, 翟妍, 桑翠琴, 王淑珍. 子宫体、乳腺双原发癌的临床病理特征[J]. 首都医科大学学报, 2019, 40(6): 857-862.
[8]	张蕴显, 王雅梅, 周萍. 乳腺癌中基于开放染色质的环状RNA互作网络构建及功能分析[J]. 首都医科大学学报, 2019, 40(6): 901-910.
[9]	白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.
[10]	张凌燕, 阮祥燕, 蔡桂举, 谷牧青, Alfred O. Mueck. 他莫昔芬治疗转染孕激素受体膜组分1乳腺癌裸鼠模型对乳腺肿瘤组织Ki-67表达的影响[J]. 首都医科大学学报, 2019, 40(4): 533-538.
[11]	王月姣, 阮祥燕, 谷牧青, 蔡桂举, 李雪, 张凌燕, Alfred O. Mueck. 他莫昔芬治疗乳腺癌异种移植瘤裸鼠子宫病理改变[J]. 首都医科大学学报, 2019, 40(4): 539-543.
[12]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[13]	陈妮娜, 范怡畅, 尚昆, 杨婧, 曹邦伟. 血清血脂及载脂蛋白浓度与乳腺癌分子分型及Ki-67表达水平的相关性研究[J]. 首都医科大学学报, 2019, 40(2): 191-194.
[14]	李雪, 阮祥燕, 谷牧青, 蔡桂举, 赵越, Alfred O. Meuck. 孕激素受体膜组分1促进雌孕激素诱导的乳腺癌细胞增生的研究——雌二醇与周期序贯及连续联合比较[J]. 首都医科大学学报, 2019, 40(2): 237-243.
[15]	徐泉, 刘玉洁, 潘钰, 郑秀瑗, 刘静民, 孙小花, 邹丽丽, 马丽娜, 严红松. 生物电阻抗测试频率对乳腺癌相关淋巴水肿定量评估的影响[J]. 首都医科大学学报, 2018, 39(5): 747-751.